Navigation Links
The European Myeloma Platform Reports New Survival data for,Revlimid Presented at the International Myeloma Workshop in Greece

BRUSSELS, Belgium and KOS, Greece, June 29, 2007 /PRNewswire/ -- The European Myeloma Platform (EMP) says updated data for previously treated patients on REVLIMID (lenalidomide) plus the steroid dexamethasone shows median survival of 35 months, nearly three years. The data are pooled from two large randomized controlled Phase III trials that enrolled more than 700 patients from nearly 100 clinical sites worldwide. These updated results were presented at the 11th International Myeloma Workshop in Kos, Greece.

"Here in Kos we are seeing what is truly a paradigm shift in treatment for multiple myeloma patients," said Greetje Goossens, EMP member and leader of the Belgium myeloma support group. "The experts here are saying that nearly three years of median over all survival for REVLIMID patients is the longest they have seen in myeloma to-date from large clinical trials."

This is the first major medical meeting since REVLIMID, an oral breakthrough therapy, was approved in Europe earlier this month for multiple myeloma patients. It has been approved for the past year in the United States. Previously it was reported that for newly diagnosed patients in a large randomized Phase III trial, REVLIMID with low dose dexamethasone demonstrated an unprecedented 98% one year survival in patients under 65 and 95% one year survival in patients 65 and over. Investigators characterized this as the best one-year survival data they have seen in a large phase 3 study in myeloma.

"We are very excited about these data," said Dr. Rolf Pelzing of Germany, Vice-Chairperson, EMP. "There is no cure for myeloma, but from personal experience, I can say that the duration of survival and the quality of life is improving significantly for many of us as demonstrated by the powerful new data that were presented at the meeting in Kos."

Multiple myeloma is a rare form of cancer of plasma cells. It is the second most comm
'"/>




Page: 1 2

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Malvern initiates European user group meetings for chemical imaging
6. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
7. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
8. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
9. Inspire Announces Presentations at Two European Scientific Conferences
10. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
11. Archimedes Pharma Presents Positive Efficacy and Safety Data on Nasalfent at European Association for Palliative Care Congress
Post Your Comments:
(Date:9/22/2014)... , Sept. 22, 2014  Inovio Pharmaceuticals, ... it has initiated a phase I clinical trial ... evaluate the safety, tolerability, and immunogenicity of INO-3106. ... which causes most aerodigestive cancers. Aerodigestive ... vocal cords, and parts of the esophagus and ...
(Date:9/22/2014)... NEW YORK , Sept. 22, 2014 ... signed an exclusive, global license agreement with Plasma ... of its proprietary plasma fractionation process. Concurrently, the ... its intention to strategically refocus and rebrand the ... to pursue a national listing for its common ...
(Date:9/22/2014)... , Sept. 22, 2014 Auxilium Pharmaceuticals, ... biopharmaceutical company, today announced that its Board of ... and conditional proposal from Endo International plc ("Endo") ... legal advisors, has unanimously determined it is not ... existing merger agreement with QLT Inc. ("QLT") and ...
Breaking Medicine Technology:Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6Auxilium Provides Transaction Update 2Auxilium Provides Transaction Update 3Auxilium Provides Transaction Update 4Auxilium Provides Transaction Update 5Auxilium Provides Transaction Update 6
... Henry Schein, Inc. (NASDAQ: HSIC ), the ... office-based practitioners, today announced that its disaster relief hotline ... experience operational, logistical or financial issues as a result ... number for all dental, medical and animal health customers ...
... Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX ), announced ... the Jefferies 2011 Global Healthcare Conference on June 9, 2011 ... The live and archived webcast of the company presentation can ... Center at www.idenix.com . Please log in approximately 5-10 ...
Cached Medicine Technology:Henry Schein Disaster Relief Hotline Remains Open for Customers Affected by Devastating Storms 2Henry Schein Disaster Relief Hotline Remains Open for Customers Affected by Devastating Storms 3
(Date:9/22/2014)... out to be an old acquaintance: a certain module ... been considered an anchor protein. The researchers report their ... Essential: importing enzymes into peroxisome , Peroxisomes are ... fatty acids and cellular toxins. In order for them ... be imported into the peroxisomes first. The bulk is ...
(Date:9/22/2014)... of more than 30,000 nurses across Europe show that ... more likely to rate the standard of care delivered ... of their hospitals safety and omit necessary patient care. ... and the National Nursing Research Unit (NNRU) at King,s ... 450 hospitals across 12 European countries, was part of ...
(Date:9/22/2014)... Following 14 months of field ... Clearwater Clinical announced the general release of ... for smartphones. ClearSCOPE enables health professionals to capture ... and smartphone. , ENT and Urology specialists developed ... over the cost, encumbrance and slow innovation cycle ...
(Date:9/22/2014)... Thousand Oaks dentist , Dr. Sharon ... Invisalign is a type of orthodontic treatment that can ... can vary based on the extent of the dental ... needed. During this promotion, Dr. Shamoiel is offering complete ... of the adult population has an unhealthy bite, and ...
(Date:9/22/2014)... The invitation only Summit held ... 60 industry executives and thought leaders from major ... Retro Fitness, and Xsport Fitness. Also in attendance ... marketing agencies and private equity investors representing over ... , The Summit highlighted best practices for solving ...
Breaking Medicine News(10 mins):Health News:The accelerator of molecular motors 2Health News:Nurse survey shows longer working hours impact on quality of care 2Health News:ClearSCOPE 2.0 Endoscope Adaptor for Smartphones Announced; Endoscopic Video Capture Reinvented 2Health News:Thousand Oaks Cosmetic Dentist, Sharon Shamoiel DDS, Is Now Offering a Special on Invisalign 2Health News:Motionsoft Concludes Inaugural 2014 Technology Summit 2Health News:Motionsoft Concludes Inaugural 2014 Technology Summit 3
... ARBOR, Mich.---Scientists have discovered a molecular assistant called Spy that ... purposes. Bacteria are widely used to manufacture proteins used ... job. Many proteins fall apart and get cut up inside ... useless tangles instead of folding properly, as they must in ...
... FL 14 February, 2011 Elsevier / MEDai, ... announced today the launch of the latest version of ... The new version will feature an expanded set of ... new predictions: ICU Admission Prediction, Length of Stay Prediction ...
... two pesticides, rotenone and paraquat, and Parkinson,s disease. People ... times more often than non-users. The study ... National Institute of Environmental Health Sciences (NIEHS), which is ... Parkinson,s Institute and Clinical Center in Sunnyvale, Calif. ...
... 11 (HealthDay News) -- The U.S. Food and Drug ... that provides three-dimensional images of the breast for cancer ... an upgrade to Massachusetts-based Hologic Inc.,s FDA-approved two-dimensional system, ... breasts. The 3-D images may help physicians more accurately ...
... , SUNDAY, Feb. 13 (HealthDay News) -- People who ... may be protecting themselves from developing Parkinson,s disease, a ... are found in a variety of foods such as ... touted as protective against some diseases because of their ...
... News) -- Hunters who use tree stands can stay safe ... a study on tree stand safety. The reminder comes ... from tree stands and four died during the recent deer-hunting ... falls in Alabama in a single year, said the state,s ...
Cached Medicine News:Health News:Quest for designer bacteria uncovers a 'Spy' 2Health News:Elsevier/MEDai enhances real-time clinical surveillance system for hospitals 2Health News:NIH study finds 2 pesticides associated with Parkinson's disease 2Health News:FDA Approves First 3D Mammogram Device 2Health News:Berries May Offer Sweet Protection Against Parkinson's Disease 2Health News:Berries May Offer Sweet Protection Against Parkinson's Disease 3Health News:Spate of Hunter Injuries Spurs New Call for Tree Stand Safety 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: